A 30-d course of oral administration of a semipurified extract of the root of Withania somnifera consisting predominantly of withanolides and withanosides reversed behavioral deficits, plaque pathology, accumulation of β-amyloid peptides (Aβ) and oligomers in the brains of middle-aged and old APP/PS1 Alzheimer's disease transgenic mice. It was similarly effective in reversing behavioral deficits and plaque load in APPSwInd mice (line J20). The temporal sequence involved an increase in plasma Aβ and a decrease in brain Aβ monomer after 7 d, indicating increased transport of Aβ from the brain to the periphery. Enhanced expression of low-density lipoprotein receptor-related protein (LRP) in brain microvessels and the Aβ-degrading protease neprilysin (NEP) occurred 14-21 d after a substantial decrease in brain Aβ levels. However, significant increase in liver LRP and NEP occurred much earlier, at 7 d, and were accompanied by a rise in plasma sLRP, a peripheral sink for brain Aβ. In WT mice, the extract induced liver, but not brain, LRP and NEP and decreased plasma and brain Aβ, indicating that increase in liver LRP and sLRP occurring independent of Aβ concentration could result in clearance of Aβ. Selective down-regulation of liver LRP, but not NEP, abrogated the therapeutic effects of the extract. The remarkable therapeutic effect of W. somnifera mediated through up-regulation of liver LRP indicates that targeting the periphery offers a unique mechanism for Aβ clearance and reverses the behavioral deficits and pathology seen in Alzheimer's disease models.
A 30-d course of oral administration of a semipurified extract of the root of Withania somnifera consisting predominantly of withanolides and withanosides reversed behavioral deficits, plaque pathology, accumulation of β-amyloid peptides (Aβ) and oligomers in the brains of middle-aged and old APP/PS1 Alzheimer's disease transgenic mice. It was similarly effective in reversing behavioral deficits and plaque load in APPSwInd mice (line J20). The temporal sequence involved an increase in plasma Aβ and a decrease in brain Aβ monomer after 7 d, indicating increased transport of Aβ from the brain to the periphery. Enhanced expression of low-density lipoprotein receptor-related protein (LRP) in brain microvessels and the Aβ-degrading protease neprilysin (NEP) occurred 14-21 d after a substantial decrease in brain Aβ levels. However, significant increase in liver LRP and NEP occurred much earlier, at 7 d, and were accompanied by a rise in plasma sLRP, a peripheral sink for brain Aβ. In WT mice, the extract induced liver, but not brain, LRP and NEP and decreased plasma and brain Aβ, indicating that increase in liver LRP and sLRP occurring independent of Aβ concentration could result in clearance of Aβ. Selective down-regulation of liver LRP, but not NEP, abrogated the therapeutic effects of the extract. The remarkable therapeutic effect of W. somnifera mediated through up-regulation of liver LRP indicates that targeting the periphery offers a unique mechanism for Aβ clearance and reverses the behavioral deficits and pathology seen in Alzheimer's disease models.
herbal extract | dementia | neurodegenerative disease A lzheimer's disease (AD) is characterized by progressive dysfunction of memory and higher cognitive functions. Pathological hallmarks include senile plaques, neurofibrillary tangles, dystrophic neurites, gliosis, and neuroinflammation. Cholinesterase inhibitors and the NMDA antagonist memantine, the commonly used drugs for AD, provide symptomatic relief but do not alter the course of disease. No curative treatment is available, and research focuses on drugs for slowing disease progression or providing prophylaxis.
The majority of AD cases are sporadic in nature. The small fraction of familial cases are caused primarily by mutations in three genes: amyloid precursor protein (APP), presenilin1 (PS1), and presenilin 2 (PS2). These mutations result in abnormal processing of APP and increased generation of β amyloid peptide 1-42 (Aβ42), which aggregates as β sheets (1) . Treatment strategies have focused on reducing β-amyloid load through (i) inhibition of γ-or β-secretases or activation of α-secretase; (ii) inhibition of Aβ aggregation; (iii) activation of proteases, such as neprilysin (NEP); and (iv) active and passive immunotherapy (2, 3) .
Among other mechanisms, influx and efflux of brain Aβ are regulated by receptor for advanced glycation end products (RAGE) and low-density lipoprotein receptor-related protein (LRP), respectively (4) . The soluble form of LRP in plasma (sLRP) is a peripheral sink for Aβ that aids its sequesteration. In AD, plasma sLRP and LRP1 at the blood-brain barrier are reduced, whereas RAGE expression is increased, resulting in accumulation of brain Aβ (5, 6).
Thus, enhancing Aβ transport across the blood-brain barrier and Aβ sequestration by sLRP can help reduce AD pathology.
Traditional systems of medicine, such as Ayurveda, offer a knowledge base that can be drawn on to develop novel therapeutic strategies. Withania somnifera (WS), also known as Ashwagandha, is a nootropic agent that promotes cognition, including memory (7) . Withanolide A and withanoside IV from WS roots help promote neurite outgrowth in cultured neurons and in rodents injected with Aβ 25-35 (8, 9 ). Here we demonstrate that a WS extract reverses behavioral deficits and plaque pathology and reduces the Aβ burden in middle-aged and old APP/PS1 mice through up-regulation of liver LRP, leading to increased clearance of Aβ. The therapeutic effects of WS were reproducible in APPSwInd J20 mice, another model of AD, in which behavioral deficits were reversed and plaque load decreased significantly.
Results

WS Reverses Behavioral Deficits and Plaque Pathology in APP/PS1 and
APPSwInd J20 Mice. A 30-d course of treatment with WS extract (Fig. S1 ) led to complete reversal of the behavioral deficits seen in the radial maze task in middle-aged (9-10 mo old) male APP/ PS1 mice (Fig. 1A ) and in the Morris water maze in APPSwInd J20 mice (Fig. S2 A-D) . Old APP/PS1 mice (23-24 mo) showed enhanced performance on the radial arm maze starting on day 21 of treatment and increasing progressively up to day 30 (Fig. 1B) . Amyloid plaques were eliminated in the cortex (CT) and hippocampus (HP) of middle-aged APP/PS1 mice of both sexes ( Fig. 1C and Fig. S3A ) and substantially reduced in old mice as detected by stereologic examination after immunostaining with antibody to Aβ42, ubiquitin, silver, or thioflavin ( Fig. 1C and Fig.  S4 A and B) . In 8-to 10-mo-old APPSwInd J20 mice, plaque density was reduced by 58% in CT and 63% in HP (Fig. S2E) . Cerebral amyloid angiopathy (CAA), observed as deposition of Aβ in brain microvessels, seemed substantially reduced in old APP/PS1 (Fig. S5 A-C) and APPSwInd J20 (Fig. S5D) mice.
WS Decreases Aβ Levels and Promotes Disaggregation of Oligomers
in APP/PS1 Mice. Aβ42 levels were reduced in middle-aged male APP/PS1 mice by 77% in CT and 78% in HP and in old mice by 49% in CT and 52% in HP (Fig. 1D ). Brain Aβ40 (Fig. S6A ) and plasma Aβ42/40 were significantly reduced as well ( Fig. 1E and Fig. S6B ). Similar reductions in brain and plasma Aβ42 levels were seen in middle-aged female APP/PS1 mice (Fig. S3B ). Aβ oligomers (dimers, trimers, and tetramers), which contribute significantly to AD pathology (10, 11) , were significantly decreased in the CT of APP/PS1 mice treated with WS for 30 d (Fig. 1F) .
APP Processing Is Not Altered by WS. To rule out the possibility that therapeutic effects of WS could be caused by repression of APP expression (both transgene and WT), we quantified APP protein (Fig. S7A) , and mRNA ( Fig. S7B ) in APP/PS1 mice and found that they were unaffected by WS. We also evaluated CTFs of APP and found no change in levels of α, β, and γ CTFs (Fig.  S7C) . β-secretase (BACE) levels were unaffected as well (Fig.  S7D) , indicating that WS does not influence APP processing. Reversal of behavioral deficits in middle-aged (A) and old (B) APP/PS1 (Tg) mice measured as a significant decrease in reference memory errors (RME), correct working memory errors (CWME), and incorrect working memory errors (ICWME) on an eight-arm radial maze (RAM) task. (C) The plaque area was decreased in the CT and HP of middle-aged and old animals. Sections stained by normal IgG were used as negative controls. (D and E) Aβ42 levels were significantly reduced in the CT, HP, and plasma of middle-aged and old animals treated with WS. Aβ42 levels in WT and middle-aged and old mice were as follows: CT, 0.63 pmol/mg protein; HP, 0.30 pmol/mg protein; plasma, 0.52 pmol/100 mL and CT, 0.78 pmol/mg protein; HP, 0.33 pmol/mg protein; plasma, 0.61 pmol/100 mL, respectively. (F) A significant reduction of Aβ42 monomer and lower oligomers was seen in CT. Values are mean ± SEM (A and B) or mean ± SD (C-F), n = 10 mice. *P ≤ 0.05.
Temporal Sequence of Therapeutic Action of WS in APP/PS1 Mice.
Plaque density decreased significantly after 14 d of treatment ( Fig. 2A) . Activated microglia were observed around the plaques (Fig. S8A) . The number of activated microglia proximal to the plaques increased significantly from day 7 to day 14 and decreased thereafter (Fig. S8 A and B) . The number of microglia distal to the plaques decreased from day 7 to day 21, as did the total number of Iba-1 positive microglial cells (Fig. S8 A and B) .
Aβ42 monomer decreased after 7 d in CT, followed by decline in the levels of oligomers (dimers, trimers, and tetramers) and total Aβ42/40 after 14 d (Fig. 2 B and C) . Interestingly, plasma Aβ42/40 levels increased significantly between day 7 and day 14, possibly indicating clearance of Aβ from the brain into the circulation (Fig. 2D) .
Consequently, we examined the status of LRP, which mediates transport of Aβ from the brain into the periphery (12, 13) . Expression of LRP mRNA and protein increased significantly in CT after 14-30 d of treatment (Fig. 3A) . LRP expression increased progressively in endothelial cells, as demonstrated by colocalization of LRP with CD31, a marker of endothelial cells ( Fig. 3C and Fig. S9A ). Neuronal LRP remained unchanged (Fig. 3D ). RAGE and clusterin expression decreased significantly at 14-30 d posttreatment, whereas ApoE was unaffected (Fig. S9B) . The mRNA, protein, and catalytic activity of NEP increased only after 21 d (Fig. 3B) .
Because the decrease in brain Aβ42 monomer and increase in plasma Aβ were detected before significant enhancement of brain LRP or NEP, we examined the peripheral effects of WS. Liver NEP (16%) and LRP mRNA (57%) and plasma sLRP (46%) increased after 7 d and increased progressively up to 30 d (by 45%, 239%, and 274% respectively; Fig. 3 E and F) . Significant negative correlations was seen among cortical Aβ42, hepatic LRP and NEP, and plasma sLRP levels (Fig. 3G) .
WS Enhances LRP and NEP mRNA in WT Mice. To identify Aβ-independent effects, we treated young adult WT mice with WS and observed increased expression of hepatic, but not brain, LRP and NEP (Fig. 4A) . Plasma sLRP was increased, whereas brain and plasma Aβ were decreased (Fig. 4 B and C) , indicating that the profound effect of WS on liver LRP and NEP leads to a decrease in Aβ load even in WT mice. (Fig. 4 D and F) . Inhibition of hepatic, but not brain, NEP (Fig. S10A ) by thiorphan had no effect on Aβ levels in brain or plasma (Fig. S10C ), indicating that hepatic NEP does not play a critical role in the therapeutic effect of WS. Thiorphan had no effect on hepatic LRP (Fig. S10B ).
Discussion
The major constituents of the roots of WS are alkaloids (eg, withanine, somniferine) and steroidal lactones, withanolides, and their glycosides, withanosides. We report reversal of AD pathology in APP/PS1 mice by a partially purified WS extract consisting of 75% withanolides and 20% withanosides by increasing the clearance of the toxic Aβ peptide from the brain, promoting its sequestration in plasma and ultimately its degradation in the periphery. The aforementioned beneficial effects are associated with reversal of behavioral deficits and reduced AD pathology in very old AD Tg mice (22-24 mo old), a phenomenon not reported previously. The therapeutic benefits of WS on behavioral deficits and Aβ pathology are also confirmed in APPSwInd J20 mice, another AD mouse model. WS treatment decreased CAA in both models (Fig. S5 ). However, CAA is scarce even in old (23-24 mo) APP/PS1 mice and detectable mainly in the HP of adult APPSwInd J20 mice, and thus a thorough analysis is needed with a more suitable AD mouse model with extensive CAA, such as the vasculotropic Dutch/Iowa E693Q/D694N mutation (Tg-SwDI).
One of the first effects seen after 7 d of WS treatment is increased levels of sLRP in plasma and enhanced expression of LRP and NEP in the liver, accompanied by a concomitant increase in plasma Aβ42/40 and decrease in brain Aβ monomer levels, indicating the efflux of Aβ42/40 from the brain into plasma. Following the course of therapeutic action of WS, we see a decrease in the lower oligomers of Aβ after 2-3 wk, indicating that the disaggregation process starts with a decrease in brain Aβ42 monomer.
Cleavage of the N terminus of hepatic LRP releases extracellular domain of LRP into the plasma, where it is present as sLRP (14) and acts as a peripheral sink for Aβ. Intravenous delivery of LRP decreases Aβ42/40 in the brain, with a corresponding increase in the plasma (5) . Liver LRP mediates endocytosis of Aβ peptides present in the plasma, which are then cleared through NEP and other proteases present in the liver (15) . Indeed, the ability of WS to induce liver LRP may be extremely important, given that cell surface LRP in liver is required for the rapid systemic clearance of the toxic Aβ peptide (16) and subsequent degradation of this peptide by proteases in the liver.
In young adult (3-mo-old) WT mice, WS enhances the expression of liver LRP and NEP but has no effect on the brain. The increase in liver LRP leads to a decrease in Aβ in the brain and plasma in these WT mice, indicating that enhanced expression of liver LRP and thus of sLRP can lead to efflux of Aβ from the brain to the plasma. Selective down-regulation of liver LRP, but not NEP (Fig. 4D) , abrogates the therapeutic effect of WS and increases Aβ levels in the brain (Fig. 4 G and H) , indicating that the primary effect of WS on liver LRP and sLRP contributes to the clearance of brain Aβ. In APP/PS1 mice, WS enhances liver LRP by 57% within 7 d and by up to 239% after 30 d. Several proteases, including NEP, are involved in the degradation of Aβ in the liver. Although WS induces hepatic NEP, its inhibition does not have a profound effect on therapeutic efficacy, indicating that other proteases present in the liver can potentially degrade Aβ. The preferential effect of WS on inducing the expression of LRP in the liver but not in the brain could be due to differential penetration of the extract and/ or regulation of gene expression.
Sequentially, there were two distinct effects: before and after a decrease in brain Aβ. The early events seen at 7 d, when total brain Aβ level was not significantly decreased, include increases in liver LRP and NEP and plasma sLRP, with no change in the brain other than Aβ monomer loss. However, after 14 d, when brain Aβ levels were decreased, LRP expression increased as measured by quantitative RT-PCR and immunoblot analysis. NEP levels increased after 21 d. The increase in LRP mRNA occurs earlier and is more pronounced in the liver (a 2.5-fold increase after 21-30 d) compared with the brain (a 0.7-fold increase).
Increased production of Aβ peptides is known to depress the expression of critical genes, which is restored when Aβ levels are decreased (4) . The delayed effect of WS on the expression of brain LRP and NEP seems to indicate that a similar phenomenon might be operating here as well. This idea is supported by the lack of effect of WS on LRP and NEP expression in the brain of WT animals, unlike in the liver.
Although LRP is the major cell surface receptor for clearance of Aβ from brain interstitial fluid across the blood-brain barrier, it is also involved in the endocytosis of APP and thereby influences Aβ production within neurons (17) . In fact, AD transgenic mice crossed with mice overexpressing neuronal LRP exhibit increased soluble Aβ levels and enhanced memory deficits (18) . WS did not substantially increase neuronal LRP, although enhanced LRP staining was seen in endothelial cells lining microvessels ( Fig. 3 C  and D) . The other proteins involved in trafficking of Aβ between the brain and the periphery are RAGE and clusterin. The expression of RAGE is increased in AD. WS decreased the expression of RAGE and clusterin, the physiological and pathological chaperones that influence Aβ aggregation (19) .
We have demonstrated the profound effect of the withanosides/ withanolides in reducing amyloid load through their direct peripheral effect on liver LRP and sLRP. The remarkable effect of WS in clearing the amyloid load in familial forms of AD is of significance, given that these deposits are poorly cleared from the brain, resulting in earlier onset of the familial forms. Thus, WS may be of potential use in the treatment of familial AD.
As noted earlier, the extract used in this study is a mixture of several withanolides and withanosides, and a rather high dose was used. Notwithstanding, one of the salient features of this study is that oral administration of WS proved highly effective in reversing the behavioral deficits and pathological features in two mouse models of AD. Purification and identification of the active principles of WS is required such that the effective dosage of administration can be decreased. It is likely that more than one compound will be necessary to bring about the therapeutic action. Because WS is composed of several compounds, it is possible that pathways other than those examined in this study may contribute to the ultimate therapeutic effect seen. Nevertheless, the potent effect of WS in rapidly clearing Aβ is mainly related to its effect in the periphery through increases in the levels of liver LRP and sLRP, indicating that targeting the periphery for Aβ clearance may provide a unique mechanism for rapid elimination of Aβ, eventually leading to reversal of behavioral deficits in AD transgenic mice.
Materials and Methods
Preparation of Plant Extract. The powdered root of W. somnifera obtained from an authenticated source (Arya Vaidya Sala) was serially extracted with chloroform-methanol and dried to remove all traces of the solvent. The residual material, comprising 75% withanolides and 20% withanosides, is referred to as WS extract. The LC-MS fingerprint of the extract is shown in Fig. S1 .
Animals and Treatment. Transgenic mice B6C3-Tg (APPswe,PSEN1)85Dbo/J were procured from Jackson Laboratory. An additional group of APPSwInd mice (J20 line) was used to confirm data on cognition and amyloidosis. WT and APP/PS1 or APPSwInd J20 mice were divided into two groups for treatment with vehicle or WS extract. WS extract was suspended in ethanol (1 g/mL), and a single daily oral dose of 1 g/kg body weight was administered for 7-30 d, with no animal receiving more than 30 μL of ethanol per day. Control animals received and equal volume of ethanol. Details are provided in SI Materials and Methods.
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SI Materials and Methods
Antibodies. Antibodies to β-amyloid peptides 1-42 (12F4, monoclonal), 1-40 (11A50-B10, monoclonal), and 1-16 (6E10, monoclonal) were purchased from Covance. Antibodies to neprilysin (NEP) (AB5458, polyclonal) and β-secretase (BACE) (AB5940, polyclonal) were purchased from Chemicon International. Antibodies to β-tubulin and LRP1 (N-terminal) were obtained from Sigma-Aldrich. Antibodies to C-terminal fragments (CTFs) of amyloid precursor protein (APP) (anti-APP-CT20) and lipoprotein receptor-related protein (LRP) (anti-LRP; light-chain mouse mAb [5A6]) were obtained from EMD Biosciences, and antibody to Aβ42 (H-43, polyclonal) was obtained from Santa Cruz Biotechnology. Antibody to CD31 (rat anti-mouse CD31, polyclonal for immunohistochemistry) was purchased from BD Pharmingen. Antibodies to Iba-1 and glial fibrillary acidic protein (GFAP) were purchased from Wako Pure Chemical and Cell Signaling Technology, respectively. Nova Red, 3,3′,5,5′-tetramethylbenzidine (TMB) substrate kit, and secondary antibodies were purchased from Vector Laboratories. All other chemicals or reagents were of analytical grade and were obtained from Sigma-Aldrich, Merck, or Qualigens.
The antibodies used for specific experiments are described below. Antibodies Aβ(1-42), 12F4 (1.5 μg/mL) and Aβ (1-40), 11A50-B10 (1.5 μg/mL) were used as coating antibodies for Aβ42 and Aβ40, respectively, in ELISA. Antibody 12F4 was also used for Aβ42 immunohistochemical staining in APP/PS1 mice. Aβ42 (H-43; 0.5 μg/mL) was used as a detection antibody for Aβ42 and Aβ40 in ELISA. LRP1 N-terminal antibody was used for immunoblot analysis for sLRP and immunofluorescence for LRP and anti-LRP, and mAb (5A6) was used for detection of LRP in cortex and liver by immunoblot analysis. 6E10 was used for detection of monomers, oligomers, and APP as well as for immunohistochemistry of Aβ in APPSwInd mice. Anti-APP-CT20, anti-BACE (AB5940), and anti-NEP (AB5458) were used for detection of CTFs (α, β, γ), BACE, and NEP, respectively, by immunoblot analysis. Anti-CD31, anti-Iba-1, and anti-GFAP were used for immunofluorescence labeling of endothelial cells, microglial cells, and astrocytes, respectively.
Experimental Animals. Experiments were performed with two different mouse transgenic lines. One of the lines used overexpressed chimeric APP (Mo/HuAPP695swe) and mutant human presenilin 1 (PS1-dE9) under a prion promoter (APP/PS1 mice). The other line (APPSwInd mice, line J20) overexpressed Swedish (670/671 KM→NL ) and Indiana (717 V→F ) mutations of human APP driven by the platelet-derived growth factor β promoter in neurons (1). WT and APP/PS1 transgenic mice were bred at the animal facility of the National Brain Research Centre, and all animal experiments were carried out in accordance with institutional guidelines for the use and care of animals under approval of the Animal Ethics Committee. Experiments using 8-to 10-mo-old APPSwInd mice were performed at the Laboratory of Cerebrovascular Research, Montreal Neurological Institute, were approved by the Animal Ethics Committee, and adhered to guidelines of the Canadian Council of Animal Care. All efforts were made to minimize animal suffering, to reduce the number of animals used, and to use alternatives to in vivo techniques if available. We used APP/PS1 mice of both sexes and varying age groups, namely 3-4 mo (young adults), 9-10 mo (middle-aged adults), and 23-24 mo (old adults). The time course, LRP downregulation, and NEP inhibition experiments used 13-to 16-moold APP/PS1 mice. Animals were genotyped for the presence of transgene as described previously (2, 3) . In brief, DNA was amplified by PCR to generate one product from the transgene (if present) and one product from the mouse genome as control for the integrity of the extracted DNA. Experiments with J20 line mice used 8-to 10-mo-old (middle-aged) males and females in equal numbers. Age-matched, nontransgenic WT littermates were used as controls for both lines.
Tissue Processing. At the end of the experimental period, the mice were anesthetized with ether, and blood was collected through cardiac puncture. The mice were then decapitated, and the liver and brain were dissected out. The cerebral hemispheres were separated, and the left hemisphere was fixed in buffered paraformaldehyde (4% wt/vol) and used for histology. Cortex and hippocampus were dissected from the right hemisphere, flashfrozen in liquid nitrogen, and used for biochemical and molecular biological studies.
Behavioral Assessment. Radial arm maze. Spatial and working memory was assessed using a radial arm maze (RAM) (4, 5) in WT and APP/PS1 mice (10 mice in each group). The RAM was designed with eight identical and equally spaced arms (42 cm long × 11.5 cm wide) radiating from a central octagonal platform (32 cm in diameter) with a recessed food cup (1 cm from the end and 1.5 cm deep). The RAM apparatus was elevated to a height of 28 cm from the ground and placed in a small, well-lit room that contained a number of visual cues. At the entrance to each arm was a door that could be controlled using strings. The behavioral paradigm was carried out for 27 d and included habituation (acclimatization and pretraining for 8 d) and acquisition for 19 consecutive days with one trial per day. Four arms were randomly assigned to be baited, with the restriction that no more than one pair of adjacent arms was baited or unbaited. This paradigm was maintained throughout the experiment. The trial was terminated when all of the pellets were consumed or 5 min had elapsed, whichever was earlier. Three types of errors were scored (6, 7): reference memory errors, defined as the number of first entries into an unbaited arm; "correct" working memory errors, defined as the number of reentries into a baited arm; and "incorrect" working memory errors, defined as the number of reentries into an unbaited arm (8) . Morris water maze. Spatial memory was assessed in WT and APPSwInd mice (10 mice per group) using a modified version of the Morris water maze adapted for transgenic mice (9) . A circular pool (1.4 m diameter) was filled with water (kept at 17 ± 1°C), and a transparent platform (15 cm in diameter) was placed in one quadrant of the pool. The water was made cloudy with powdered skim milk, and the room was lit optimally with visuospatial cues on the walls. The test was performed over 8 d and consisted of a cued task (visible platform, days 1-3) in which the platform was kept 1 cm above the water level. Mice were randomly started from each of the three positions (south, east, and north) and underwent three trials of 60 s each. On the fourth day, the spatial task (hidden platform, days 4-8) was initiated. For this purpose, the location of the platform and that of the visual cues were changed, and the platform was submerged 1 cm below the water surface. Mice were subjected to three trials of 90 s each, with an intertrial interval of 45 min, to find the platform and were guided to and allowed to stay on it for 5 s on the first day if the allotted time was exceeded. On the eighth day, at 2 h after the last training, a probe trial of 60 s in which the platform was removed was administered, and the mice were allowed to swim freely. The behavior of the mice was recorded with a Ganz FC62D video camera and a 2020 Plus tracking system and analyzed with Water 2020 software (HVS Image). Recorded parameters included latency (time taken to reach the platform, days [4] [5] [6] [7] [8] , and for the probe trial, the number of crossings, percent distance traveled, and percent time spent in the target quadrant (where the platform was previously located). Swim speed was measured to evaluate the animals' locomotor activity and visual acuity. The animals were allowed to dry under a heat lamp after each trial to avoid hypothermia, and all experiments were started at the same time each day.
Immunoblot Analysis. Brain regions were homogenized in 0.1 M potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose and protease inhibitor mixture. Plasma was isolated from the blood. An aliquot of the brain homogenate and plasma were used for ELISA. The remaining portion of the brain homogenate was centrifuged at 1,000 × g for 10 min to obtain the postnuclear supernatant. This was then further centrifuged at 100,000 × g for 1 h to obtain the cytosol. Protein concentrations in the total brain homogenate, postnuclear and cytosolic fractions were estimated by the dye-binding method (10) before ELISA or immunoblot analysis. The postnuclear fraction was resolved on SDS/PAGE and probed with antibodies to NEP, BACE, LRP, APP, and its CTFs. Blots were normalized with β-tubulin. The postnuclear fraction was also used for evaluating NEP activity. Plasma was used for detection of sLRP by immunoblot analysis. Cytosol was resolved on 10-20% Tris-tricine gels for the separation of β-amyloid oligomers (11), transferred to PVDF membranes, and probed with 6E10 antibody.
ELISA for Quantitation of Aβ Level. Total Aβ42 and 40 levels in plasma and brain were quantitated by ELISA (12, 13) using 12F4 and 11A50-B10 as capture antibodies for Aβ 42 and Aβ 40 , respectively. β-amyloid H-43 was used as a detection antibody for both Aβ 42 and Aβ 40.
NEP Activity Assay. NEP activity was assayed spectrophotometrically after the cleavage of internally quenched fluorogenic substrate dansyl-D-Ala-Gly-Phe(NO 2 )-Gly. The cleavage by NEP occurs at Gly-Phe (NO 2 ) bond, which relieves the fluoroscent dansyl group from Phe (NO 2 ), resulting in increased fluorescence (14, 15) . In brief, 100 μM dansyl-D-Ala-Gly-Phe (NO 2 )-Gly prepared in 2-(N-morpholino)ethanesulfonic acid 4-morpholineethanesulfonic acid (Mes) buffer (pH 6.5) was added to 50 μg of protein sample in a final volume of 100 μL. Fluorescence was recorded every 30 s using Varioskan Flash spectral scanning reader (Thermo Electron). Activity was measured as change in fluorescence per mg of protein per unit of time.
RNA Isolation and Quantitative Real-Time PCR of APP, NEP, ApoE, RAGE, Clusterin, and LRP. Total RNA was isolated from the cortex and liver of mice using TRI reagent (16) and cDNA was synthesized using random hexamers. Real-time PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) in accordance with the manufacturer's instructions. All reactions were carried out in triplicate, and negative controls without the template were run simultaneously. 18S rRNA was used as an internal control for normalization. Data were analyzed using the comparative threshold cycle (ΔΔCt) method. The following primer sequences were used for quantitative real time-PCR: LRP1: forward, 5′-CCACTATGGATGCCCCTAAAACTT-3′; reverse, 5′-GCAATCTCTTT CACCGTCACACC-3′; NEP: forward, 5′-GAAATTCAGCCAAAGCAAGC-3′; reverse, 5′-TCG-GCCTGAGGAATAAAATG-3′; APP N-terminal: forward, 5′-ACTG ATGGCAACGCCGGGCTG-3′; reverse, 5′-CTCCCA-CTTTCCATTCTGCACATT-3′; APP C-terminal: forward, 5′-CAGTACACATCCATCCATCATGGC-3′; reverse, 5′-ATTC-TCAT ATCCGTTCTGCTGCAT-3′; clusterin: forward, 5′-AG-CAGGAGGTCTCTGACAATGAG C-3′; reverse, 5′-GGCTT-CCTCTAAACTGTTGAGCAAG-3′; ApoE: forward, 5′-CAC AAGAACTGACGGCACTGATG-3′; reverse, 5′-GTCGGTT-GCGTAGATCCTCCATG-3′; RAGE: forward, 5′-GCGCAG-ACCCCTGAACACA-3′; reverse, 5′-GGCAG AGATGGCAC-AGGTCAAG-3′.
Histology. Brain tissue was fixed in 4% paraformaldehyde (PFA; wt/vol) overnight, and serial coronal sections were cut with a cryostat. Every tenth section was used for stereologic assessment of plaque load. Plaques were visualized by silver (17) and thioflavin stainng (18) and immunohistochemistry for Aβ42 using the 12F4 antibody. In APP J20 mice, one hemisphere was processed for paraffin embedding after fixation with 4% PFA and cut into 5-μm-thick sections. Aβ deposits in brain tissue and blood vessels were immunodetected with the 6E10 antibody. Immunohistochemistry was also performed for ubiquitin, Iba-1, GFAP, CD31, and LRP as described previously (19, 20) after heat-induced epitope retrieval using antigen-unmasking solution, with nonimmune IgG as a negative control. Aβ42, ubiquitin, and silver stained sections were visualized using a Leica DFC 320 camera attached to a Leica DM RXA2 microscope. For APP/PS1 mice, the percent area covered by plaque/ubiquitin deposits was quantified using Leica IM50 software by counting the number of plaque/ubiquitin deposits in a defined region; data are expressed as percent area covered by plaques. For the APPSwIn mice, images were quantified using MetaMorph 6.1r3 (Universal Imaging), and data are expressed as percent plaque load.
Quantitation of Microglia Proximal and Distal to the Plaques. Immunohistochemistry for microglia was performed using Iba-1 antibody followed by thioflavin S staining on every fifth section. Stereologic analysis was done by determining the number of activated microglia near to and far from the plaques using IM50 software. The Iba-1-positive cells in contact with the plaques were counted as near, and those present at a distance greater than twice the diameter of the plaques were counted as far.
Down-Regulation of Liver LRP. Antisense and random (scrambled) oligodeoxynucleotides (oligos) with a phorophorthioate backbone (PS-ODNs) were used for down-regulation as described previously (21) . The following sequences of the three PS-ODNs were used:
19mer (anti-LRP1): 5′-(_P = S)TGATTTGGTCTCTGCAG-GC-3′ 23mer (anti-LRP1): 5′-(_P = S)GTGTGGGCCGATGCAA-ACAGCAG-3′ 21mer (random): 5′-(_P = S)GAGAAGGTTGTGTGATCT-TCA-3′ APP/PS1 mice were divided into two groups. One group was given a mixture of antisense oligos in equal amounts (18.75 μg of 19mer + 18.75 μg of 23mer = 37.5 μg total) i.p. at 12-h intervals for 7 d. The remaining group received 37.5 μg of the random 21mer PS-ODN in a similar fashion. A daily dose of the plant extract (1 g/kg body weight) was administered orally at 1 h after the first dose of oligos for 7 d. Animals were killed 24 h after the last injection of PS-ODNs.
Inhibition of Liver NEP Activity. Thiorphan was used to inhibit NEP activity in the liver. APP/PS1 mice were divided into two groups. One group was given i.p. thiorphan (50 mg/kg, dissolved in 0.9% saline containing 25% ethanol, vol/vol) for 7 d, and the other group received vehicle in a similar fashion. A daily dose of the plant extract (1 g/kg body weight) was administered orally at 1 h after thiorphan administration for 7 d. Animals were killed at 24 h after the last injection of thiorphan.
Liquid Chromatography-Mass Spectrometry. Liquid chromatography-electrospray ionization-mass spectrometry of Withania somnifera (WS) extract was recorded in positive-and negativeion modes using an Esquire 3000-plus mass spectrometer (Bruker Daltonics) consisting of two octopoles, followed by an ion trap. The WS extract was dissolved in methanol and run through a Phenomenex C18 column (4.6 mm × 50 mm, 4 μm particle size, 90 Å pore size) using acetonitrile or methanol/ water/0.1% formic acid (CH 3 CN or CH 3 OH/H 2 O/0.1% HCOOH) in the positive-ion mode. The negative-ion mode spectrum was recorded using methanol/water/10 mM ammonium acetate (CH 3 OH/H 2 O/10 mM NH 4 COOCH 3 ) as the eluting solvent. The flow rate was maintained at 0.2 mL min −1 with detection at 226 nm in both positive-and negative-ion modes.
Helium was used as the gas for collision-induced dissociation experiments. The UV and total ion chromatogram of WS extract in positive-and negative-ion modes was recorded using an Esquire 3000-plus mass spectrometer (Bruker Daltonics) consisting of two octapoles followed by an ion trap. The data were processed using Esquire version 3.1 (Bruker Daltonics).
Data Analysis and Statistics. Immunoblots were normalized with their respective loading controls. Statistical data analysis was done using the Student t test for comparison of two groups. ANOVA was used to compare multiple groups, followed by a post hoc Dunnett or Student-Newman-Keul test. A P value ≤ 0.05 was considered statistically significant. Correlation analysis was performed using Pearson's correlation method. Fig. S1 . Liquid chromatography-electrospray ionization-mass spectroscopy of WS extract in positive-ion mode. The extract was dissolved in methanol and subjected to chromatography in a column using acetonitrile/water/0.1% formic acid (A) or methanol/water/0.1% formic acid (C). The various peaks obtained were analyzed at different time intervals in gradients of water:acetonitrile (B) or water:methanol (D). 
